Compare DWSN & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | DWSN | MSLE |
|---|---|---|
| Founded | 1952 | N/A |
| Country | United States | Canada |
| Employees | N/A | 17 |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.5M | 146.9M |
| IPO Year | 1995 | N/A |
| Metric | DWSN | MSLE |
|---|---|---|
| Price | $4.26 | $6.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 107.3K | 30.5K |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.85 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $145,773,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.72 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.27 | $5.50 |
| 52 Week High | $5.54 | $13.39 |
| Indicator | DWSN | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 58.94 | 38.58 |
| Support Level | $1.63 | $5.50 |
| Resistance Level | $4.93 | $8.59 |
| Average True Range (ATR) | 0.35 | 0.46 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 75.97 | 20.11 |
Dawson Geophysical Co provides seismic data acquisition services mainly to providers of multi-client data libraries and directly to onshore oil and natural gas exploration and development companies in the continental U.S. and Canada. The demand for seismic services is largely influenced by drilling and completion activity, exploration budgets, and prevailing and anticipated crude oil and natural gas prices. Its data acquisition crews serve companies engaged in the exploration and development of oil and gas on land and in land-to-water transition areas. The business operates through two reportable segments, with U.S. operations generating the majority of revenue and Canada operations contributing additionally.
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.